Early Short-Term Use of Different Doses of Corticosteroid in Hospitalized Pediatric Patients with Coronavirus Disease 2019 Pneumonia

 

 Buy Article Permissions and Reprints

Abstract

Objective Encouraged by reports of favorable outcomes following the use of corticosteroids in patients with moderate-to-severe coronavirus 2019 (COVID-19) pneumonia, we aimed to present our experience with early short-term corticosteroid use at our center in pediatric patients with COVID-19 pneumonia.

Methods One hundred and twenty-nine pediatric patients were included in the study. Patients were divided into four groups according to the type and dose of corticosteroids given: Group 1 (those receiving dexamethasone 0.15 mg/kg/d); Group 2 (those receiving methylprednisolone 1 mg/kg/d); Group 3 (those receiving methylprednisolone 2 mg/kg/d); and Group 4 (those receiving pulse methylprednisolone 10–30 mg/kg/d).

Results Of 129 patients, 19 (14.7%) patients were assigned to Group 1, 30 (23.3%) patients to Group 2, 30 (23.3%) patients to Group 3, and 50 (38.8%) patients to Group 4. Thirty-two (24.8%) patients were followed in the pediatric intensive care unit (PICU), of whom 13 (10%) required mechanical ventilation, and 7 (%5.4) died. In Group 4, the hospitalization length was significantly longer than in other groups (p < 0.001, p < 0.001). No significant difference was found among the groups in terms of mortality (p = 0.15). The most common comorbidity was obesity (33%). A significant association was found between the presence of comorbidity and mortality (p < 0.001). All patients who died had an underlying disease. Cerebral palsy was the most common underlying disease among the patients who died. Worsening of lymphopenia was significant in patients with severe COVID-19 pneumonia at the time of transfer to the PICU (p = 0.011).

Conclusion Although children usually have a milder course of COVID-19 than adults, underlying diseases and obesity increase the severity of disease manifestations also in children. Further studies are needed to define the exact role of corticosteroids in COVID-19 patients.

Publication History

Received: 15 July 2022

Accepted: 26 October 2022

Article published online:
01 December 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Papamanoli A, Yoo J, Grewal P. et al. High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia. Eur J Clin Invest 2021; 51 (02) e13458
  CrossrefPubMedGoogle Scholar
• 2 Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID19): cases and latest updates. Accessed April 7, 2020 at: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html
  PubMedGoogle Scholar
• 3 McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infect Dis 2020; 7 (04) ofaa105
  CrossrefPubMedGoogle Scholar
• 4 Rodriguez-Garcia JL, Sanchez-Nievas G, Arevalo-Serrano J, Garcia-Gomez C, Jimenez-Vizuete JM, Martinez-Alfaro E. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. Rheumatology (Oxford) 2021; 60 (01) 399-407
  CrossrefPubMedGoogle Scholar
• 5 Fadel R, Morrison AR, Vahia A. et al; Henry Ford COVID-19 Management Task Force. Early short-course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis 2020; 71 (16) 2114-2120
  CrossrefPubMedGoogle Scholar
• 6 Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395 (10223): 473-475
  CrossrefPubMedGoogle Scholar
• 7 Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol 2020; 11: 1446
  CrossrefPubMedGoogle Scholar
• 8 Sterne JAC, Murthy S, Diaz JV. et al; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 2020; 324 (13) 1330-1341
  CrossrefPubMedGoogle Scholar
• 9 Horby P, Lim WS, Emberson JR. et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384 (08) 693-704
  CrossrefPubMedGoogle Scholar
• 10 Tomazini BM, Maia IS, Cavalcanti AB. et al; COALITION COVID-19 Brazil III Investigators. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. JAMA 2020; 324 (13) 1307-1316
  CrossrefPubMedGoogle Scholar
• 11 Jeronimo CMP, Farias MEL, Val FFA. et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis 2021; 72 (09) e373-e381
  PubMedGoogle Scholar
• 12 Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007; 56 (04) 1010-1013
  CrossrefPubMedGoogle Scholar
• 13 Russo L, Lumeng CN. Properties and functions of adipose tissue macrophages in obesity. Immunology 2018; 155 (04) 407-417
  CrossrefPubMedGoogle Scholar
• 14 Zeng F, Huang Y, Guo Y. et al. Association of inflammatory markers with the severity of COVID-19: a meta-analysis. Int J Infect Dis 2020; 96: 467-474
  CrossrefPubMedGoogle Scholar
• 15 Simonnet A, Chetboun M, Poissy J. et al; LICORN and the Lille COVID-19 and Obesity study group. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring) 2020; 28 (07) 1195-1199
  CrossrefPubMedGoogle Scholar
• 16 Tsankov BK, Allaire JM, Irvine MA. et al. Severe COVID-19 infection and pediatric comorbidities: a systematic review and meta-analysis. Int J Infect Dis 2021; 103: 246-256
  CrossrefPubMedGoogle Scholar
• 17 Hengeveld PJ, Khader AO, de Bruin LHA. et al. Blood cell counts and lymphocyte subsets of patients admitted during the COVID-19 pandemic: a prospective cohort study. Br J Haematol 2020; 190 (04) e201-e204
  CrossrefPubMedGoogle Scholar
• 18 He Z, Zhao C, Dong Q. et al. Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int J Infect Dis 2005; 9 (06) 323-330
  CrossrefPubMedGoogle Scholar
• 19 Zhang JJ, Cao YY, Tan G. et al. Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. Allergy 2021; 76 (02) 533-550
  CrossrefPubMedGoogle Scholar
• 20 Chen R, Sang L, Jiang M. et al; Medical Treatment Expert Group for COVID-19. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. J Allergy Clin Immunol 2020; 146 (01) 89-100
  CrossrefPubMedGoogle Scholar
• 21 Gao YD, Ding M, Dong X. et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy 2021; 76 (02) 428-455
  CrossrefPubMedGoogle Scholar